-
INTERIM DIVIDEND FOR THE SIX MONTHS ENDED 30 JUNE 20222022-08-26
-
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 20222022-08-26
-
VOLUNTARY ANNOUNCEMENT - EXCLUSIVE LICENSING AND CO-DEVELOPMENT AGREEMENT WITH GHDDI2022-08-22
-
DATE OF BOARD MEETING2022-08-16
-
VOLUNTARY ANNOUNCEMENT - LICENSING AGREEMENT WITH TIUMBIO2022-08-08
-
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 20222022-08-02
-
CHANGE OF ADDRESS OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG AND CHANGE OF ADDRESS OF HONG KONG BRANCH SHARE REGISTRAR AND TRANSFER OFFICE2022-07-28
-
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 20222022-07-05
-
VOLUNTARY ANNOUNCEMENT - DRUG REGISTRATION APPROVAL OF “PALBOCICLIB CAPSULES”2022-07-04
-
COMPANY INFORMATION SHEET2022-06-27
-
VOLUNTARY ANNOUNCEMENT - EQRX'S MARKETING AUTHORIZATION APPLICATION OF AUMOLERTINIB IN EGFR-MUTATED NON-SMALL CELL LUNG CANCER ACCEPTED BY UK'S MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY2022-06-15
-
POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON FRIDAY, JUNE 10, 20222022-06-10
